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in nude mice with 131I gelatin microspheres
(131I-GMSs) following intratumoral injection
Chuan-Chao Li1, Jun-Lin Chi1, Yu Ma2, Jian-Hong Li3, Chuan-Qin Xia4*, Lin Li5, Zhuo Chen6 and Xiao-Li Chen1*Abstract
Introduction: The aim of this study was to investigate the effects of 131I gelatin microspheres (131I-GMS) on human
breast cancer cells (MCF-7) in nude mice and the biodistribution of 131I-GMSs following intratumoral injections.
Methods: A total of 20 tumor-bearing mice were divided into a treatment group and control group and received
intratumoral injections of 2.5 mci 131I-GMSs and nonradioactive GMSs, respectively. Tumor size was measured once
per week. Another 16 mice received intratumoral injections of 0.4 mci 131I-GMSs and were subjected to single
photon emission computed tomography (SPECT) scans and tissue radioactivity concentration measurements on day
1, 4, 8 and 16 postinjection. The 20 tumor-bearing mice received intratumoral injections of 0.4 mci [131I] sodium
iodide solution and were subjected to SPECT scans and intratumoral radioactivity measurements at 1, 6, 24, 48 and
72 h postinjection. The tumors were collected for histological examination.
Results: The average tumor volume in the 131I-GMSs group on post-treatment day 21 decreased to 86.82 ± 63.6%,
while it increased to 893.37 ± 158.12% in the control group (P < 0.01 vs. the 131I-GMSs group). 131I-GMSs provided
much higher intratumoral retention of radioactivity, resulting in 19.93 ± 5.24% of the injected radioactivity after
16 days, whereas the control group retained only 1.83 ± 0.46% of the injected radioactivity within the tumors at 1 h
postinjection.
Conclusions: 131I-GMSs suppressed the growth of MCF-7 in nude mice and provided sustained intratumoral
radioactivity retention. The results suggest the potential of 131I-GMSs for clinical applications in radiotherapy
for breast cancer.
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Selective internal radiotherapy (SIRT), using radioactive
microspheres or particles, is a rapidly developing tech-
nology in the field of minimally invasive interventional
cancer therapy. The major advantage of internal radiation
over external radiation is that, by directly delivering radio-
pharmaceuticals into tumor tissue, internal radiation can
maximize the antineoplastic effects on tumor tissue, while
preventing normal tissues from radiation damage [1].
In addition, tumor cells can be continuously exposed
throughout the cell cycle to the radiation of radionuclides* Correspondence: xiachqin@163.com; zean_z@aliyun.com
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unless otherwise stated.carried by the microspheres or particles. In recent years,
radiolabeled microspheres and particles have been used
in clinical settings or animal studies, including 90Y glass
or resin microspheres [2,3], 32P glass microspheres or
colloids [4,5], 166Ho-loaded glass microparticles [6],
186/188Re glass microspheres [7] and various biodegradable
microspheres, such as 166Ho poly(L-lactic acid) micro-
spheres(PLLA-MS) [8], and these microspheres and parti-
cles showed excellent anti-tumoral effects and a good
level of safety after intraarterial or intratumoral injec-
tions. There are two forms of commercially available
90Y microspheres — TheraSphere® and SIR-Spheres® —
which were approved by the FDA, respectively, in 2000
for use in radiation treatment for inoperable hepatocellu-
lar carcinoma and in 2002 for the treatment of colorectalhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that intraarterial infusion of 90Y microspheres is an effect-
ive and safe alternative for treating patients with inoper-
able hepatocellular carcinoma and metastatic liver cancer
originating from colorectal carcinoma, breast cancer and
endocrine system cancers [2,3,10-13]. In addition to radio-
embolization, direct intratumoral injection of radiolabeled
microspheres or particles is also an effective and safe
method for treating malignancies [5,14], and this treatment
is especially suitable for treating solid tumors characterized
by hypo-vasculature [15] or for which intraarterial inter-
ventional therapy is infeasible, such as breast cancer and
prostate cancer. As we know, radioembolization is defined
as the injection of radiolabeled microspheres or particles
by use of percutaneous superselective catheterization of
the tumor vasculature, so it is a very challenging work
and it may result in severe adverse effect once the non-
target vessels are embolized. Up to now, percutaneous
radioembolization is only used in the internal radio-
therapy of liver malignant tumors, and it is infeasible
in the treatment of many other tumors, such as breast
cancer and prostate cancer, in which image-guided super-
selective catheterization of the tumor vessels almost
can’t implement.
The radioactive microspheres consist of two parts: a
radionuclide and carrier. Although the application of 90Y
microspheres in radiotherapy for malignancies has
already obtained considerable success, its drawbacks are
also obvious. For example, as 90Y is a pure beta emitter
and does not produce gamma rays, the biodistribution
of 90Y microspheres cannot be directly determined by
SPECT scans [16]. In addition, the high density of glass
increases the likelihood of premature intravascular set-
tling and falling back into the gastrointestinal tract, thus
resulting in radiation-related gastrointestinal side effects
[17,18], and the non-biodegradability of glass or resin
could hamper the repeated administration of micro-
spheres. Therefore, biodegradable microspheres labeled
with radioisotopes that simultaneously yield βemissions
and γ rays have attracted increasing attention in recent
years. In fact, some biodegradable microspheres have
been successfully developed, such as poly (L-lactic acid)
microspheres loaded with 166Ho or 186/188Re, which
showed high degrees of in vitro and in vivo stability and
good safety profiles [8,19,20].
We have been studying radioiodine-labeled gelatin mi-
crospheres in recent years. [131I] Sodium iodide (Na131I)
oral solution is readily obtained, as it is routinely used
for the treatment of hyperthyroidism and differentiated
thyroid carcinoma. The major advantage of 131I over
other radionuclides is that dissociative iodine mainly
accumulates in the thyroid or is directly excreted via the
kidneys [21-24] and rarely remains in other tissues, so
oral administration of a single dose of more than 100mci Na131I solution is relatively safe for patients with
differentiated thyroid carcinoma or thyrotoxicosis, and
the radiation dose to the family members of patients
treated with up to 600 MBq of radioiodine is well below
the recommended dose constraints if safety instructions
are complied with well [25,26]. Gelatin microspheres are
a type of derivative of collagen with a good level of bio-
compatibility, and they can be labeled with a high con-
centration of radioiodine. In our previous studies, we
injected 131I labeled gelatin microspheres and 131I, 125I
dual-labeled gelatin microspheres into the liver paren-
chyma of rabbits, and we found that the injected micro-
spheres mainly accumulated around the injection site,
and the small amount of de-labeled radioiodine did not
cause severe damage to other tissues [27,28]. In the
present study, we evaluated use of 131I-GMSs as an ef-
fective radiopharmaceutical for the treatment of trans-




The preparation of 131I-GMSs have been previously de-
scribed in detail [27]. In brief, 6 mL of gelatin solution
(15 wt%) was dropwise added to 40 mL of liquid paraffin
(Kelong Chemical Reagent Co. Ltd., Chengdu, China) with
0.4 mL of Span 80 (Shenyu Chemical Reagent Co. Ltd.,
Chongqing, China), and stirred at 600 rpm in a 50°C water
bath, after 20 min minutes later, the solutions were rapidly
cooled to 4°C with continuous stirring. Then cross-bonding
was performed by adding 2 mL of 25% glutaraldehyde
(25%, Kermel Chemical Reagent Co. Ltd., Tianjin, China)
with stirring for 30 minutes. Solid gelatin microspheres
were collected after rinsed in acetone (Changlian Chemical
Reagent Industries, Ltd., Chengdu, China) and sieved the
microspheres of size 30 to 50 microns with a stainless
steel sieve. Then we labeled 131I by a modification of the
chloramine-T method. Briefly, 50 mg of gelatin micro-
spheres was added into 190 μL of phosphate-buffered sa-
line (pH 7.0) for swelling in test tubes. 10 min later, 20 μL
of 131I-sodium-iodine solution (37 GBq/mL) and 200 μL
of chloramine-T solution (Bodi Chemical Reagent Co.
Ltd., Tianjin, China) (20 mg/mL) were added. After mix-
ing for 30 min with a vortex at room temperature, 200 μL
of sodium pyrosulfite solution (Jiangbei Chemical Reagent
Industries, Ltd., Wuhan, China) (15 mg/mL) was added to
stop the reaction. Then the mixtures was centrifuged at
1000 r/min for 4 min to separate the 131I- gelatin micro-
spheres. Finally, the products were washed seven times
with normal saline and sterilized by 60Co irradiation.
Human breast cancer xenografts in nude mice
This study was approved by the animal ethics committee
of Sichuan University. Nude mice 4–5 weeks age (BABL/c)
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Sichuan University. The nude mice, 4–5 animals per
cage, were housed in pathogen-free conditions, with
sterile water and granular food at libitum. The air hu-
midity and temperature were maintained at 50%-70%
and 20-29°C, respectively. Human breast cancer cell
line MCF-7 was purchased from China Center for Type
Culture Collection (CCTCC, Wuhan, China), and the
cells were cultured in RPMI-1640 medium supplemented
with 10% fetal calf serum (Thermo-Fisher Biochemical
Products [Beijing] Co., Ltd., Beijing, China) and were in-
cubated at 37°C in a 5% CO2 incubator. After growing ex-
ponentially for 1 week, the MCF-7 cells were harvested by
trypsinization and were washed with normal saline, and
approximately 1 × 107 MCF-7 cells were then suspended
in 0.1 mL of normal saline and injected into the mammary
fat pads of each female nude mouse.
Tumor volume and body weight measurements
A total of 20 tumor-bearing nude mice were randomly
divided into 2 groups and were used to evaluate the effi-
cacy of treatment. When the tumors reached approxi-
mately 1.0 cm −1.5 cm in diameter, microspheres were
suspended in 0.1 mL of glucose solution (25%) and were
slowly injected into the centers of the tumors using a
1 mL syringe and a 27G needle. The treatment group
(n = 10) and the control group (n = 10) were treated with
2.5 mci (92.5 MBq) 131I microspheres and the same
amount of nonradioactive microspheres, respectively. The
preparation of 131I-GMSs has been previously described
in detail [27].
The animals were monitored for the treatment’s effects
on tumor size and body weight for 7 weeks or until the
animals reached the maximum allowable tumor burden.
The tumor size was measured with Vernier calipers in
two dimensions, and tumor volume was calculated as
v =1/2ab2, where a and b are the largest and smallest
diameters of the tumor, respectively, and v is the tumor
volume in cubic centimeters. The therapeutic effects of
131I-GMSs were evaluated by comparing the tumor volume
of the treatment group with that of the control group.
In addition, the body weights of the animals were also
measured to evaluate the radiation toxicity.
Tissue radioactivity concentration measurements and
image acquisition
Twenty nude mice were injected with 0.4 mci (14.8 MBq)
131I-GMSs and were used to determine the tissue biodis-
tribution of 131I on days 1, 4, 8 and 16 after 131I-GMSs
injections (4 animals for each time point). Under
anesthesia by intraperitoneal injection of 0.1 ml chloral
hydrate (West China Hospital), a single photon emission
computed tomography (SPECT) scan was obtained, and
SPECT-CT images were acquired using a gamma camera(Skylight SPECT camera, Philips Co., Ltd., Amsterdam,
the Netherlands) in the Nuclear Medicine Department of
West China Hospital. Then, the animals were sacrificed
by cervical dislocation, and samples of the liver, lung,
spleen, kidney, muscle, bone, thyroid gland and whole
tumor were excised and weighed carefully. Radioactivity
was measured by a γ counter (No. 262 Industry, Ltd.,
Xi’an, China). In addition, 1 ml of blood was collected
from the orbital vein and was used for γ counting.
The intratumoral retention of injected radioactivity
was expressed as a percentage of the injected dose in
the whole tumor; radioactivity concentrations in other
organs and in serum were expressed as percentages
of the injected dose per gram (% ID/g) and per milliliter,
respectively.
To evaluate the role of 131I-GMSs in the intratumoral
retention of radioactivity, another 20 tumor-bearing
nude mice were used as a control group. After intratu-
moral injection of 0.4 mci [131I] sodium iodide oral solu-
tion (Na131I),SPECT-CT images were acquired, and the
intratumoral radioactivity levels were measured at 1, 4,
24, 48 and 72 h postinjection (4 animals for each time
point).
Histological findings
Tumor samples were fixed by immersion in 10% forma-
lin solution for 48 h, embedded in paraffin, sectioned
and stained with hematoxylin and eosin (HE) for histo-
logical examination. The tumor samples at 28 days and
35 days after injection were also examined.
Data analysis
The results of the tumor volumes are expressed as the
means ± SDs and were analyzed by one-way ANOVA
using SPSS software, version 19.0, and the level of sig-
nificance was set at a P value < 0.05.
Results
Scanning electron microscopic images of 131I-GMSs
Figure 1 shows the scanning electron microscopic im-
ages of 131I-GMSs. The microspheres were washed with
normal saline 7 times after labeling to minimize physical
absorption, and the final labeling rate of 131I was 57.5 ±
2.62%. The microspheres were uniform in shape, with a
diameter of 30–50 μm and good divergence.
Tumor volumes in the 131I-GMSs treatment group and
control group
Figure 2 shows the changes in tumor volumes in the
131I-GMSs treatment group and the control group. On
the day of microsphere injection, the average tumor vol-
umes in the 131I-GMSs treatment group and the control
group were 0.87 ± 0.39 cm3 and 0.79 ± 0.06 cm3, respect-
ively, and the difference was not significant (P > 0.05).
Figure 1 Scanning electron microscopic images of 131I
gelatin microspheres.
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the treatment group decreased to 0.63 ± 0.39 cm3, which
was 86.82 ± 63.6% of the initial volume (P < 0.01 com-
pared to the control group), whereas the average tumor
volume in the control group increased to 7.03 ± 0.95 cm3,
which was 893.37 ± 158.12% of the pre-treatment volume.
The rates of tumor growth in the 131I-GMSs treatmentFigure 2 Tumor volumetric assessment of the effect of
131I-GMSs on MCF-7 xenografts in nude mice. The points
represent means, and the bars represent standard errors.
Comparisons between control and 131I-GMSs group were
analyzed by one way ANOVA, and a P value < 0.05 is regarded
as significance. It is obvious that intratumoral injection of 2.5
mci 131I-GMSs significantly suppressed the growth of tumors
compared with control group, #: P <0.01.group and the control group over this period were −0.01 ±
0.02 cm3/d and 0.30 ± 0.05 cm3/d, respectively. It is obvi-
ous that intratumoral injection of 2.5 mci 131I-GMSs sta-
tistically significantly suppressed the growth of tumors
compared with the control group. At the end of the 7th
week (the endpoint of the study), the average tumor vol-
ume of the treatment group was 1.27 ± 0.55 cm3, which
was 186.2 ± 55.2% of their initial volume. The control
group animals were sacrificed on day 21 because of exces-
sive tumor burden.
Biodistribution of 131I
The radioactive concentrations after injection of 131I-
GMSs are summarized in Table 1. The radioactivity in
the tumors was much higher than in any other tissue.
The highest radioactivity concentration outside the tu-
mors was found in the lung, which had 2.67% of the
injected radioactivity on the 1st day and 1.89% on the 4th
day, but this level rapidly decreased to 0.34% by the 8th
day. The radioactivity concentrations in other tissues,
such as the kidney, liver, spleen, bone, muscle, serum, and
even thyroid gland, were quite low throughout the obser-
vation period. The intratumoral retention of injected
radioactivity (% ID) after injection of 131I-GMSs was
43.29 ± 5.27%, 29.28 ± 3.72%, 24.71 ± 7.28% and 19.93 ±
5.24% at 1, 4, 8 and 16 days, respectively, whereas the
intratumoral retention of injected radioactivity (% ID) after
injection of Na131I solution was only 1.83 ± 0.46%, 0.60 ±
0.29%, 0.45 ± 0.07%,0.14 ± 0.02% and 0.06 ± 0.01% at 1, 6,
24, 48 and 72 h after injection, respectively (Table 2).
SPECT-CT fusion images
A SPECT scan was obtained on day 1, 4, 8 and 16 for
the 131I-GMSs group and at 1, 6, 24, 48 and 72 h for the
Na131I solution group, respectively. SPECT imaging
showed that the radioisotopes were concentrated in the
tumor for the whole observation period, and no accu-
mulation of nuclides was noted in the other tissues,
including the thyroid gland and the urinary system
(Figure 3A-D). However, SPECT imaging showed dif-
fused biodistribution of the injected radioactivity through-
out the whole body 1 h after intratumoral injection of
Na131I solution (Figure 4A), followed by gradual accumu-
lation of 131I in the thyroid area and decreases in radio-
activity in other tissues (Figure 4B,C). At 48 h after
injection, the radioactivity was mainly concentrated in
thyroid area, and no radioactivity was noted in any other
tissue (Figure 4D,E). The intratumoral radioactivity was
quite low throughout the observation period in this group
(Figure 4A-E).
Pathological findings
Pathological examination showed that the injected mi-
crospheres concentrated around the injection site, with
Table 1 Biodistribution after intratumoral injections of 131I-GMSs (%, mean ± SD)
Time Liver Thyroid Lung Kidney Spleen Bone Muscle Serum Tumor
1 d 0.09 ± 0.03 0.33 ± 0.20 2.67 ± 0.42 0.57 ± 0.34 0.1 ± 0.04 0.51 ± 0.10 0.12 ± 0.07 0.16 ± 0.06 43.29 ± 5.27
4 d 0.07 ± 0.02 0.12 ± 0.05 1.89 ± 0.58 0.69 ± 0.30 0.04 ± 0.01 0.05 ± 0.02 0.02 ± 0.01 0.09 ± 0.01 29.28 ± 3.32
8 d 0.01 ± 0.00 0.02 ± 0.01 0.34 ± 0.25 0.05 ± 0.03 0.06 ± 0.01 0.11 ± 0.03 0.02 ± 0.01 0.04 ± 0.01 24.71 ± 7.28
16 d < 0.01 0.02 ± 0.00 0.10 ± 0.06 0.02 ± 0.01 0.01 ± 0.00 0.09 ± 0.01 0.02 ± 0.01 0.05 ± 0.01 19.93 ± 5.24
The biodistribution of radioactivity after intratumoral injections of 131I-GMSs. The intratumoral retention of injected radioactivity into the tumors was expressed as
the percentage of the injected dose in the whole tumor; tissue concentrations of other organs were expressed as the percentage of the injected dose per gram
(% ID)/g, and the radioactivity in the serum was expressed as the percentage of the injected dose per milliliter.
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spheres were degraded gradually after injection (Figure 5A,
B,C,D,E and F). At 35 days after injection, microspheres
degraded to irregular shape, with some parts of mi-
crospheres missing. However, some microspheres still
retained their complete morphology (Figure 5D). In treat-
ment group, there were no visible microspheres at 49 days
after injection of 131I-GMSs (Figure 5F).
Body weight
The 131I-GMSs group showed mild body weight loss
of 12.16 ± 10.1% from postinjection to day 21, but they
gradually gained weight thereafter (Figure 6).
Discussion
Breast cancer is the second most common non-skin can-
cer in women worldwide, with an incidence of 10.4%,
and it has the highest incidence among all cancer types
in women in the USA, with one in every 8–10 women
being affected during her lifetime [29]. Prospective trials
have clearly demonstrated the efficacy of breast conser-
vation therapy (BCT) for early breast cancer, showing
that it offers equivalent local control and long-term sur-
vival compared with mastectomy [30-33]. As an indis-
pensable part of BCT, radiation therapy has a significant
role in the treatment of breast cancer [34,35]. However,
the rationality of conventional whole breast irradiation
(WBI) has gradually been questioned. On the one hand,
local recurrence tends to occurs at, or in proximity to,
the tumor bed, and other sites of ipsilateral breast recur-
rence occur rarely, in 3%-4% of all cases [36]; on the
other hand, radiation therapy limited to the region of
the tumor bed (APBI) produced long-term local control
and survival rates comparable to those from WBI inTable 2 The comparisons of the intratumoral retention of rad
131I-GMSs 1d 4d
43.29 ± 5.27 29.28 ± 3.72
Na131I solution 1 h 6 h
1.83 ± 0.46 0.60 ± 0.29
The comparison of the intratumoral retention of radioactivity after intratumoral inje
intratumoral retention of injected radioactivity, maintaining 19.93 ± 5.24% of the inj
was cleared rapidly from the tumors after injection of Na131I solution. By 1 h, the N
radioactivity within the tumors.selected low-risk patients [37]. Accelerated partial breast
irradiation (APBI) is an approach that treats only the
tumor bed plus a 1- to 2 -cm margin, rather than the
whole breast, thus irradiating a smaller volume, giving a
higher radiation dose per fraction to the tumor bed. This
process shortens the treatment time significantly [38].
Interstitial breast brachytherapy is an APBI technique
that has been practiced for more than 20 years and that
has the most extensive follow-up [39]. Many prospective
studies have reported low local recurrence with brachy-
therapy at 5 and 10 years, comparable to WBI [37,40-42].
For example, Polgár et al. reported their experience with
APBI, providing the longest follow-up in the literature for
the HDR multi-catheter techniques, and the 5- and 12-
year local recurrence rates were only 4.4% and 9.3%, re-
spectively [42]. However, the implementation of catheter
insertion in multi-catheter interstitial brachytherapy re-
quires a high level of skill on the part of the operator and
the support of sophisticated imaging techniques. In con-
trast, direct interstitial injection of radiopharmaceuticals is
relatively easy to implement. As 131I gelatin microspheres
are a biodegradable material and can be injected repeat-
edly, they could have potential clinical value in treating
the tumor bed after breast conservation surgery. There-
fore, in this study, we evaluated the effectiveness of
131I-GMSs in MCF-7 tumors after direct injection into
these tumors in nude mice. Additionally, we studied the
biodistribution of dissociative 131I following the degrad-
ation of the microspheres.
Long-term intratumoral retention of radiation sources
is essential for effective brachytherapy of malignancies,
as it maximizes the antineoplastic effects on tumor tis-
sue for longer periods. In the present study, the diameter
of the injected microspheres (30–50 μm) (Figure 1) wasioactivity (%, mean ± SD)
8d 16d
24.71 ± 7.28 19.93 ± 5.24
24 h 48 h 72 h
0.45 ± 0.07 0.14 ± 0.02 0.06 ± 0.01
ctions of 131I-GMSs and Na131I solution.131I-GMSs provided sustained
ected radioactivity within the tumors after 16 days. In contrast, radioactivity
a131I solution–treated group retained only 1.83 ± 0.46% of the injected
Figure 3 The results of SPECT imaging at 1 (A), 4 (B), 8 (C) and 16 days (D) after intratumoral administration of 131I-GMSs. The injected
radioactivity concentrated in the tumors, and no accumulation of radioiodine was noted by SPECT scan in other tissues.
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ture in tumor tissue, which effectively prevented escap-
ing of the microspheres from the tumors. Our research
showed that 131I-GMSs provided sustained intratumoral
radioactivity retention. The intratumoral radioactivity level
in the 131I-GMSs group was 19.93 ± 5.24% of the injected
dose on day 16 postinjection but only 1.83 ± 0.46% in
the control group at 1 h after injection (Table 2). This
sustained intratumoral retention of radioactivity after
intratumoral injection of 2.5 mci 131I-GMSs resulted in
a significantly slower tumor growth rate. On day 21, theFigure 4 The results of SPECT imaging at 1 (A), 6 (B), 24 (C), 48 (D) an
oral solution.average tumor volume in the control group was 893.37 ±
158.12% of the pre-treatment volume, whereas the tumor
volume in the treatment group was only 186.2 ± 55.2% of
that before injection at the end of 7th week (Figure 2).
The safety profile of internal radiotherapy is largely
dependent of the in vivo biodistribution of the radio-
activity. As the most straightforward method of bringing
radionuclides into tumors, direct intratumoral injection
of radiopharmaceuticals can maximize radiation damage
to the tumor tissue, while sparing toxicity to the critical
structures that might be nearby or superficial to thed 72 h (E) after the administration of [131I] sodium iodide
Figure 5 Pathological examination at 1 (A), 16 (B), 28(C) and 35(D) days after the injection of 0.4 mci 131I gelatin microspheres, at
21 days after administration of unlabeled microspheres (E) and at 49 days after administration of 2.5 mci 131I-GMSs (F). (HE stain;
original magnification, ×100 in A, B, D and F; ×200 in C and × 400 in E).
Figure 6 The average body weight in 131I-GMSs group.
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activity level was significantly higher than that in any
other tissue throughout the study (Table 1). The lung
was the only tissue, other than the tumor, that showed
relatively high radioactivity concentrations, which were
2.67 ± 0.42% and 1.89 ± 0.58% of the injected dose per
gram (% ID/g) at 1 day and 4 days postinjection, respect-
ively, but this level decreased rapidly to 0.34 ± 0.25% at
8 days postinjection.
As gelatin microspheres are a type of biodegradable
carrier of radionuclides, the biodistribution of de-labeled
131I should be evaluated dynamically, along with the deg-
radation of the microspheres. The biodistribution study
showed that the concentrations of radioactivity in the
liver, spleen, kidney, bone, muscle, and even thyroid gland
were quite low throughout the entire observation period
(Table 2), suggesting that gradual degradation did not
cause abundant de-labeling of 131I from the microspheres.
In recent years, studies have shown the potential of gelatin
microspheres used as carriers of drugs or cytokines. The
degradation period of gelatin in vivo can be controlled by
changing its degree of cross-linking [44,45], thus enabling
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kines [46-48]. When gelatin microspheres are used as car-
riers of radionuclides in brachytherapy for malignancies, it
is worth noting that the degradation period should be reg-
ulated according to the half-lives of the radionuclides, thus
preventing release of the radionuclides in large quantities
from the microspheres due to premature degradation of
the microspheres.
131I simultaneously yields γ-rays (1%, 0.364 Mev) and β-
emissions (99%, 0.606 Mev). Although the low-energy γ-
rays are almost negligible for the treatment of tumors, they
might be useful in determining the biodistribution of mi-
crospheres. Studies have demonstrated the potential of
166Ho-PLLA-MS, another γray emitter, for predicting the
biodistribution of the same microspheres. The distribution
of scout doses and treatment doses of 166Ho-PLLA-MS
were nearly identical, suggesting that a scout dose of 166Ho-
PLLA-MS pretreatment could be used to predict the bio-
distribution of a treatment dose [49]. It is expected that if
used in the radioembolization of liver malignancies, an
intraarterial injection of a small dose of 131I-GMSs pretreat-
ment could also be used to predict the biodistribution of a
treatment dose of 131I-GMSs, which would be helpful in
recognizing patients contraindicated for radio-embolization
due to elevated lung shunting fractions [50].
The antitumoral effect and the process of the degrad-
ation of the 131I microspheres were confirmed by a
histological examination. At 21 days postinjection in the
group received non-radioactive microspheres, the tu-
mors showed hyper-cellular neoplastic cells, with signifi-
cant increased nuclear-cytoplasmic ratio, and no signs of
necrosis were observed (Figure 5E). 7 weeks after injec-
tion of 131I-GMSs in treatment group, the tumor tissue
showed large area of necrosis, with only very small
amounts of residual tumor cells (Figure 5F). At 35 days
after injection, there were still large number of micro-
spheres within the tumors (Figure 5D). In our previous
studies, the microspheres which were injected into the
parenchyma of liver of rabbits could still be observed by
histological method even 32 days( 4 half-lives) after in-
jection [27,28]. Perhaps much more effort is needed to
retard the degradation of the microspheres, thus minim-
izing the de-labeling of radioiodine.
In conclusion, our research shows that intratumoral
injection of 131I labeled gelatin microspheres significantly
suppressed tumor growth in a nude mouse model of
human breast cancer. The injected radioactivity mainly
accumulated within the tumors, and along with the deg-
radation of 131I-GMSs, the radioactivity concentration in
all other tissues was quite low throughout the study. Al-
though a lot more work remains to be done, these results
suggest the potential clinical value of intratumoral injec-
tions of 131I-GMSs in the treatment of tumor beds after
breast conservation surgery.Abbreviations
GMSs: Gelatin microspheres; SIRT: Selective internal radiotherapy;
SPECT: Single photon emission computed tomography; CT: Computed
tomography.
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